VRG Therapeutics

VRG Therapeutics is a regional leader in preclinical research and development, specializing in the creation of custom cell lines and bioassays for the biopharmaceutical industry. The company operates in the cell and gene therapy (CGT) market, leveraging a world-class directed evolution platform to optimize natural peptides and proteins. These optimized peptides and proteins are used in various pharmaceutical applications, including CAR T therapy and GMO enterobacteria. VRG Therapeutics serves biopharma companies looking for competitive advantages in their R&D processes by providing exclusive, tailor-made solutions. The business model revolves around developing and supplying these specialized products and services, generating revenue through custom orders and long-term partnerships. Additionally, VRG Therapeutics is innovating in the field of chemogenetics, creating engineered receptor-actuator pairs for novel therapeutic classes aimed at treating CNS diseases. The company also engages in drug repositioning projects to develop new therapeutic options using existing drugs.

Keywords: preclinical R&D, cell lines, bioassays, directed evolution, peptides, proteins, cell therapy, gene therapy, chemogenetics, CNS diseases.